Literature DB >> 10666024

Hyperbaric oxygen downregulates ICAM-1 expression induced by hypoxia and hypoglycemia: the role of NOS.

J A Buras1, G L Stahl, K K Svoboda, W R Reenstra.   

Abstract

Hyperbaric oxygen (HBO) is being studied as a therapeutic intervention for ischemia/reperfusion (I/R) injury. We have developed an in vitro endothelial cell model of I/R injury to study the impact of HBO on the expression of intercellular adhesion molecule-1 (ICAM-1) and polymorphonuclear leukocyte (PMN) adhesion. Human umbilical vein endothelial cell (HUVEC) and bovine aortic endothelial cell (BAEC) induction of ICAM-1 required simultaneous exposure to both hypoxia and hypoglycemia as determined by confocal laser scanning microscopy, ELISA, and Western blot. HBO treatment reduced the expression of ICAM-1 to control levels. Adhesion of PMNs to BAECs was increased following hypoxia/hypoglycemia exposure (3. 4-fold, P < 0.01) and was reduced to control levels with exposure to HBO (P = 0.67). Exposure of HUVECs and BAECs to HBO induced the synthesis of endothelial cell nitric oxide synthase (eNOS). The NOS inhibitor nitro-L-arginine methyl ester attenuated HBO-mediated inhibition of ICAM-1 expression. Our findings suggest that the beneficial effects of HBO in treating I/R injury may be mediated in part by inhibition of ICAM-1 expression through the induction of eNOS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10666024     DOI: 10.1152/ajpcell.2000.278.2.C292

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  37 in total

Review 1.  Mechanisms of the Anti-Ischemic Effect of Angiotensin II AT( 1 ) Receptor Antagonists in the Brain.

Authors:  Juan M Saavedra; Julius Benicky; Jin Zhou
Journal:  Cell Mol Neurobiol       Date:  2006-04-25       Impact factor: 5.046

2.  Hyperbaric oxygen in systemic inflammatory response.

Authors:  Haim Bitterman; Claus-Martin Muth
Journal:  Intensive Care Med       Date:  2004-03-18       Impact factor: 17.440

3.  Hyperbaric oxygen therapy reduces the severity of ischaemia, preservation and reperfusion injury in a rat model of liver transplantation.

Authors:  Nhut Quang Tran; Caterina Malcontenti-Wilson; Soukena Hammoud; Ian Millar; Chris Christophi; Vijayaragavan Muralidharan
Journal:  HPB (Oxford)       Date:  2011-11-13       Impact factor: 3.647

4.  The spin trap 5,5-dimethyl-1-pyrroline N-oxide inhibits lipopolysaccharide-induced inflammatory response in RAW 264.7 cells.

Authors:  Zili Zhai; Sandra E Gomez-Mejiba; Hua Zhu; Florea Lupu; Dario C Ramirez
Journal:  Life Sci       Date:  2012-01-17       Impact factor: 5.037

5.  Hyperbaric oxygen and sepsis: time to recognize.

Authors:  Claus-Martin Muth; Peter Radermacher; Salvatore Cuzzocrea
Journal:  Intensive Care Med       Date:  2005-07-21       Impact factor: 17.440

6.  Hyperbaric oxygen therapy and liver transplantation.

Authors:  Vijayaragavan Muralidharan; Chris Christophi
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

7.  Oxygen cycling in conjunction with stem cell transplantation induces NOS3 expression leading to attenuation of fibrosis and improved cardiac function.

Authors:  Mahmood Khan; Sarath Meduru; Rajan Gogna; Esha Madan; Lucas Citro; Muthulakshmi L Kuppusamy; Muzzammil Sayyid; Mahmoud Mostafa; Robert L Hamlin; Periannan Kuppusamy
Journal:  Cardiovasc Res       Date:  2011-10-19       Impact factor: 10.787

8.  Exposure time related oxidative action of hyperbaric oxygen in rat brain.

Authors:  Ahmet Korkmaz; Sükrü Oter; Serdar Sadir; Turgut Topal; Bülent Uysal; Mehmet Ozler; Hakan Ay; Ahmet Akin
Journal:  Neurochem Res       Date:  2007-08-21       Impact factor: 3.996

9.  Hyperbaric oxygen for cerebral vasospasm and brain injury following subarachnoid hemorrhage.

Authors:  Robert P Ostrowski; John H Zhang
Journal:  Transl Stroke Res       Date:  2011-09-01       Impact factor: 6.829

Review 10.  Bench-to-bedside review: oxygen as a drug.

Authors:  Haim Bitterman
Journal:  Crit Care       Date:  2009-02-24       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.